Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference

News > Health News

Audio By Carbonatix

4:01 PM on Monday, October 28, 2024

The Associated Press

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 28, 2024--

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET.

Interested parties can access the live webcast here. An archived copy of the webcast will be available on the events section of the company’s investor relations website for approximately 90 days.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need. Spruce is developing its product candidate, tildacerfont, an oral, second-generation CRF 1 receptor antagonist, for the treatment of congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS) and major depressive disorder (MDD). To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.

View source version on businesswire.com:https://www.businesswire.com/news/home/20241028643351/en/

CONTACT: Media

Katie Beach Oltsik

Inizio Evoke Comms

(937) 232-4889

[email protected]

Investors

Samir Gharib

President and CFO

Spruce Biosciences, Inc.

[email protected]

KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA